Search: onr:"swepub:oai:prod.swepub.kib.ki.se:118636371" >
Long-term outcomes ...
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
-
Treon, SP (author)
-
Branagan, AR (author)
-
Ioakimidis, L (author)
-
show more...
-
Soumerai, JD (author)
-
Patterson, CJ (author)
-
Turnbull, B (author)
-
Wasi, P (author)
-
Emmanouilides, C (author)
-
Frankel, SR (author)
-
Lister, A (author)
-
Morel, P (author)
-
Matous, J (author)
-
Gregory, SA (author)
-
- Kimby, E (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2009
- 2009
- English.
-
In: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 113:16, s. 3673-3678
- Related links:
-
https://europepmc.or...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m2 per day for 5 days) of fludarabine and 8 infusions (375 mg/m2 per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a very good partial response (P = .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non–Pneumocystis carinii pneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Treon, SP
-
Branagan, AR
-
Ioakimidis, L
-
Soumerai, JD
-
Patterson, CJ
-
Turnbull, B
-
show more...
-
Wasi, P
-
Emmanouilides, C
-
Frankel, SR
-
Lister, A
-
Morel, P
-
Matous, J
-
Gregory, SA
-
Kimby, E
-
show less...
- Articles in the publication
-
Blood
- By the university
-
Karolinska Institutet